Spero Therapeutics’ (SPRO) Buy Rating Reaffirmed at HC Wainwright

Spero Therapeutics (NASDAQ:SPRO)‘s stock had its “buy” rating reiterated by stock analysts at HC Wainwright in a report issued on Monday,Benzinga reports. They presently have a $5.00 price objective on the stock. HC Wainwright’s target price indicates a potential upside of 331.03% from the stock’s current price.

A number of other research analysts have also recently issued reports on the company. TD Cowen reiterated a “hold” rating on shares of Spero Therapeutics in a research report on Monday, November 18th. Cantor Fitzgerald reiterated an “overweight” rating on shares of Spero Therapeutics in a research report on Friday, November 15th.

Spero Therapeutics Stock Up 2.7 %

SPRO stock opened at $1.16 on Monday. Spero Therapeutics has a 52 week low of $1.01 and a 52 week high of $1.89. The business has a 50-day simple moving average of $1.25 and a 200 day simple moving average of $1.32. The company has a market cap of $63.24 million, a PE ratio of 16.57 and a beta of 0.59.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently made changes to their positions in the company. Vanguard Group Inc. grew its holdings in shares of Spero Therapeutics by 0.6% during the first quarter. Vanguard Group Inc. now owns 1,653,432 shares of the company’s stock worth $2,844,000 after purchasing an additional 9,675 shares in the last quarter. Acadian Asset Management LLC increased its position in shares of Spero Therapeutics by 40.6% in the second quarter. Acadian Asset Management LLC now owns 1,071,860 shares of the company’s stock valued at $1,392,000 after acquiring an additional 309,262 shares during the period. Renaissance Technologies LLC boosted its stake in shares of Spero Therapeutics by 14.2% during the 2nd quarter. Renaissance Technologies LLC now owns 975,952 shares of the company’s stock valued at $1,269,000 after purchasing an additional 121,492 shares in the last quarter. Finally, Virtu Financial LLC purchased a new position in shares of Spero Therapeutics during the 1st quarter worth approximately $31,000. Institutional investors own 25.60% of the company’s stock.

About Spero Therapeutics

Spero Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on identifying, developing, and commercializing novel treatments for multi-drug resistant (MDR) bacterial infections and rare diseases in the United States. The company’s product candidates include tebipenem pivoxil hydrobromide (HBr), an oral carbapenem-class antibiotic to treat complicated urinary tract infections, including pyelonephritis for adults; SPR206, an intravenous-administered antibiotic against MDR Gram-negative pathogens comprising carbapenem-resistant enterobacterales (CRE), acinetobacter baumannii, and pseudomonas aeruginosa, as well as negative bacterial infections in the hospital setting; and SPR720, a novel oral antibiotic agent for the treatment of non-tuberculous mycobacterial pulmonary disease.